NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study

被引：0
|
作者：
Gregorc, V. [1 ]
Ceresoli, G. L. [2 ]
Zucali, P. A. [2 ]
De Braud, F. G. [3 ]
Bajetta, E. [4 ]
Santoro, A. [2 ]
Vigano, M. G. [1 ]
Cappio, F. Caligaris [1 ]
Lambiase, A. [5 ]
Bordignon, C. [5 ]
机构：
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Ist Clin Humanitas, Dept Oncol, Milan, Italy
[3] Ist Europeo Oncol, Clin Pharmacol & New Drugs Unit, Milan, Italy
[4] IRCCS Fdn, Ist Nazl Tumori, Dept Oncol, Milan, Italy
[5] MolMed, Clin Dev, Milan, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71724-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：509 / 509
页数：1
相关论文
共 50 条
  • [31] SAFETY AND ANTITUMOR ACTIVITY OF NGR-HTNF, A SELECTIVE VASCULAR TARGETING AGENT (VTA), ADMINISTERED AT LOW DOSE IN PRE-TREATED PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC): PRELIMINARY RESULTS OF A PHASE II TRIAL
    Citterio, G.
    Santoro, A.
    Pressiani, T.
    Scalamogna, R.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 178 - 178
  • [32] Phase II study of amrubicin for previously treated patients with malignant pleural mesothelioma.
    Akagi, Kazumasa
    Ikeda, Takaya
    Nakatomi, Katsumi
    Taniguchi, Hirokazu
    Shimada, Midori
    Gyotoku, Hiroshi
    Dotsu, Yosuke
    Umeyama, Yasuhiro
    Tomono, Hiromi
    Kitazaki, Takeshi
    Fukuda, Masaaki
    Soda, Hiroshi
    Senju, Hiroaki
    Takemoto, Shinnosuke
    Yamaguchi, Hiroyuki
    Fukuda, Minoru
    Mukae, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma
    Gregorc, Vanesa
    Zucali, Paolo A.
    Santoro, Armando
    Ceresoli, Giovanni L.
    Citterio, Giovanni
    De Pas, Tommaso M.
    Zilembo, Nicoletta
    De Vincenzo, Fabio
    Simonelli, Matteo
    Rossoni, Gilda
    Spreafico, Anna
    Vigano, Maria Grazia
    Fontana, Floriana
    De Braud, Filippo G.
    Bajetta, Emilio
    Caligaris-Cappio, Federico
    Bruzzi, Paolo
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) : 2604 - 2611
  • [34] Long-term survival outcomes of a placebo-controlled phase 3 trial with NGR-hTNF in combination with best investigator choice in relapsed malignant pleural mesothelioma (MPM).
    Gregorc, Vanesa
    Lazzari, Chiara
    Bulotta, Alessandra
    Vigano, Maria Grazia
    Ghio, Domenico
    Fontana, Floriana
    Salini, Giulia
    Lambiase, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
    Lorusso, D.
    Scambia, G.
    Amadio, G.
    di Legge, A.
    Pietragalla, A.
    De Vincenzo, R.
    Masciullo, V.
    Di Stefano, M.
    Mangili, G.
    Citterio, G.
    Mantori, M.
    Lambiase, A.
    Bordignon, C.
    BRITISH JOURNAL OF CANCER, 2012, 107 (01) : 37 - 42
  • [36] Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
    Gregorc, V.
    Santoro, A.
    Bennicelli, E.
    Punt, C. J. A.
    Citterio, G.
    Timmer-Bonte, J. N. H.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    van Herpen, C. M. L.
    BRITISH JOURNAL OF CANCER, 2009, 101 (02) : 219 - 224
  • [37] Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
    D Lorusso
    G Scambia
    G Amadio
    A di Legge
    A Pietragalla
    R De Vincenzo
    V Masciullo
    M Di Stefano
    G Mangili
    G Citterio
    M Mantori
    A Lambiase
    C Bordignon
    British Journal of Cancer, 2012, 107 : 37 - 42
  • [38] Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM).
    Venkatraman, Deepti
    Anderson, Adrienne
    Digumarthy, Subba
    Lizotte, Patrick H.
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] LACK OF RESPONSE TO CHEMOTHERAPY FOR PREVIOUSLY TREATED MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Zauderer, Marjorie G.
    Kass, Samantha L.
    Sima, Camelia S.
    Ginsberg, Michelle S.
    Krug, Lee M.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S638 - S639
  • [40] A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM)
    Lee, C. W.
    Anderson, H.
    Martins, H.
    Rao, S. C.
    Sauciuc, D.
    Laurie, S. A.
    Morzycki, W.
    MacNeil, M. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345